Blockade of colony-stimulating factor-1 (CSF-1) limits macrophage infiltration and improves response of mammary carcinomas to chemotherapy. Herein we identify interleukin (IL)-10 expression by macrophages as the critical mediator of this phenotype. Infiltrating macrophages were the primary source of IL-10 within tumors, and therapeutic blockade of IL-10 receptor (IL-10R) was equivalent to CSF-1 neutralization in enhancing primary tumor response to paclitaxel and carboplatin. Improved response to chemotherapy was CD8 + T cell-dependent, but IL-10 did not directly suppress CD8 + T cells or alter macrophage polarization. Instead, IL-10R blockade increased intratumoral dendritic cell expression of IL-12, which was necessary for improved outcomes. In human breast cancer, expression of IL12A and cytotoxic effector molecules were predictive of pathological complete response rates to paclitaxel.
INTRODUCTION
Tumor-associated macrophages are associated with poor clinical outcome in most carcinomas, with clinical and preclinical data indicating that this is due largely to macrophage promotion of angiogenesis, local invasion, and increased metastatic capacity (Bingle et al., 2002; Ruffell et al., 2012a) . Because macrophages are highly dependent on the colony-stimulating factor-1 (CSF-1) and CSF-1 receptor (CSF-1R) pathway for survival in most tissues (Pollard, 2009) , there is significant interest in therapeutically targeting this pathway. In murine models, small-molecule inhibitors of CSF-1R induce tumor regression in glioblastoma multiforme (Pyonteck et al., 2013) , prevent tumor growth in cervical cancer (Strachan et al., 2013) , and partially delay growth of implanted melanoma cell lines (Mok et al., 2014 ). An aCSF-1R monoclonal antibody (mAb) has also demonstrated clinical efficacy in diffuse-type giant tumors, a disease driven by overexpression of CSF-1 and recruitment of myeloid cells (Ries et al., 2014) .
In the mouse mammary tumor virus (MMTV)-polyoma middle T (PyMT) transgenic model of luminal B-type mammary carcinoma, tumor infiltration by F4/80 + macrophages parallels disease progression (DeNardo et al., 2009) , and MMTV-PyMT mice harboring homozygous null mutations in the CSF-1 gene
Significance
Therapeutics targeting the CSF-1/CSF-1 receptor pathway are currently being evaluated clinically in multiple cancer types, either as monotherapy or in combination with standard-of-care chemotherapy. However, mechanisms by which the CSF-1/ CSF-1 receptor pathway and macrophages sustain tumor growth and/or repress response to cytotoxic therapy are unclear.
Herein we report that macrophages infiltrating mammary carcinomas are the significant source of IL-10, which in turn suppresses intratumoral dendritic cell production of IL-12 and thereby limits cytotoxic T cell responses during chemotherapy. These data reveal a role for the interaction between tumor macrophages and dendritic cells in mediating response to therapy, identify a CSF-1/IL-10/IL-12 cytokine axis for targetable intervention, and reveal possible risk stratification biomarkers for patient selection. exhibit limited tumor angiogenesis, slowed tumor progression, and inhibited pulmonary metastasis (Lin et al., 2001) . Although therapeutic depletion of macrophages from tumors with mAbs or small-molecule inhibitors targeting CSF-1 or CSF-1R, respectively, exhibits no efficacy as single agents (DeNardo et al., 2011; Strachan et al., 2013) , administration in combination with standard-of-care chemotherapy (CTX) significantly slows primary tumor growth kinetics and diminishes pulmonary metastasis (DeNardo et al., 2011) . On the basis of these data, clinical studies combining the CSF-1R small-molecule inhibitor PLX3397 and CTX are currently under way (ClinicalTrials.gov identifiers NCT01596751 and NCT01525602). Although macrophages have been found to directly promote the survival of mammary carcinoma cells in a cathepsin-dependent manner in vitro (Shree et al., 2011) , our previous studies reported that enhanced chemotherapeutic efficacy associated with CSF-1R inhibition was dependent on cytotoxic CD8 + T cells (DeNardo et al., 2011) , thus indicating a role for macrophages in suppressing a T cell response during CTX. Several studies have demonstrated that tumor-associated macrophages directly suppress CD8 + T cell activation in vitro (DeNardo et al., 2011; Doedens et al., 2010; Movahedi et al., 2010) , and CSF-1R inhibition has been found to enhance adoptive cell transfer therapy in melanoma models (Mok et al., 2014) . However, the mechanism(s) by which macrophages suppress antitumor responses, either directly or indirectly in vivo, remains unclear. Here we sought to inform ongoing clinical trials by delineating functionally significant mechanisms whereby tumor-infiltrating macrophages suppress CD8 + T cell responses during CTX.
RESULTS

Macrophages Are the Primary Source of Interleukin-10 in Mammary Carcinomas
To identify the molecular mechanisms by which macrophages limited response to CTX in mammary carcinomas, we effectively depleted macrophages through administration of aCSF-1 mAb in combination with paclitaxel (PTX) in MMTV-PyMT tumorbearing mice (Figure 1A) and examined the status of tumor vasculature (Figures S1A and S1B available online), as well as expression of immune-related genes in whole tumor tissue (Figure 1B) . Although macrophages promote formation of abnormal tumor vasculature (Stockmann et al., 2008) , we did not observe changes in density of CD31 + vessels, the ratio of pericytes to endothelial cells, or extravasation of either doxorubicin or PTX into mammary tumors, as quantitatively evaluated by immunofluorescence approaches or liquid chromatography-mass spectrometry, respectively (Figures S1C and S1D), thus indicating that improved responses to CTX were unlikely linked to improved tumor hemodynamics. Instead, gene expression data revealed decreases in several myeloid-associated genes relative to control tissue, including Il1a, Il10, Nos2, Cxcl10, Ccl3, and Ccr2, and, inversely, increased expression of Gzmb, Ccl5, Cd8a , and Il12a, consistent with our previous report of a role for CD8 + T cells in mediating response to CTX following CSF-1R inhibition (DeNardo et al., 2011) . We found no change in genes reflecting a CD4/T H 1 response (Ifng, Tbx21, and Cd4) .
Of the mRNAs exhibiting reduced expression following aCSF-1 mAb therapy, Il10 is the most strongly associated with an established immunosuppressive role in vivo (Moore et al., 2001 ). We confirmed macrophages as the primary source of interleukin (IL)-10 in untreated mammary carcinomas by evaluating fluorescence-activated cell-sorted epithelial versus stromal cell populations (Figures S1E and S1F Figure 1C ). Macrophage expression of Il10 was approximately 10-fold higher than other leukocyte populations, with an additional $1.5-fold average increase in expression by MHCII LO versus MHCII HI macrophages. We further characterized the MHCII HI and MHCII LO macrophage subsets and found that both were effectively depleted by aCSF-1 mAb treatment (Figures S1G-S1I), and exhibited similar nuclear morphology in cytospins ( Figure S1J) ; however, MHCII LO macrophages displayed increased expression of several markers associated with T H 2/M2-type programming at both the protein (MSR1, MRC1, and IL4Ra) (Figure S1K ) and mRNA (Cd163, Msr1, Mrc1, Il4ra, Arg1, and Ptgs2) levels ( Figure S1L ).
On the basis of high expression of Il10 by macrophages, and its partial correlation with M2/T H 2-type biomarkers in mammary carcinomas, we evaluated expression of IL10 in human breast cancer samples from The Cancer Genome Atlas (TCGA) data set against genes associated with presence of myeloid cells (CSF1R, CD14, and CD68) or macrophage polarization (MSR1, MRC1, and CD163). We identified significant correlation between these mRNAs, with the most significant correlation occurring for MSR1 and CD163 ( Figure 1D ). IL10 expression did not correlate with FOXP3 expression (data not shown), despite reports of regulatory T (T Reg ) cells being a critical source of IL-10 in some murine tumor models (Stewart et al., 2013) . Because the association between IL10 expression and macrophages markers was relatively weak (R < 0.23), we also evaluated the presence of IL-10 protein by immunohistochemistry in human breast cancer samples. In accordance with the gene expression correlations, we observed high expression within stromal cells, (B) Fold change in whole-tissue gene expression in tumors from PTX/aCSF-1 mAb-treated mice determined by real-time PCR using a 96-gene immune array. Only significant (p < 0.05; Mann-Whitney test) changes are shown; n R 12 mice per group. (C) Il10 mRNA expression levels from fluorescence-activated cell-sorted stromal populations isolated from untreated mice as determined by real time PCR. Data are normalized to Tbp expression and displayed as mean ± SEM with n = 8 per cell type. MØ, macrophage; mono, monocyte. (D) Correlation between IL10 expression and various myeloid-associated genes in human breast cancer samples from the TCGA data set (n = 1,161). (E) Detection of IL-10 in human breast cancer by immunohistochemistry. Fourteen CTX-naive and 9 CTX-treated patient samples were evaluated. Representative images reflecting low and high staining are displayed. (F) Immunofluorescent staining for IL-10, CD163, and DNA using Hoescht 33342 in human breast cancer. Representative images from one of three patient samples are displayed. See also Figure S1 .
including CD163
+ cells with a myeloid morphology (Figures 1E and 1F) . In contrast to murine tumor tissue, however, we also observed variable expression within tumor epithelial cells. Thus, although macrophages, in particular T H 2/M2-type macrophages, are associated with expression of IL-10 in both murine mammary carcinomas and human breast cancer, IL-10 production within human breast tumors displays increased variability and complexity. Figure S2 .
Blockade of the IL-10 Receptor Improves Response to PTX To examine whether IL-10 was functionally relevant for regulating response to CTX, we treated late-stage tumorbearing MMTV-PyMT mice with an IL-10 receptor-blocking mAb (aIL-10R; clone 1B1.3A) prior to and throughout a chemotherapeutic regimen of 10 mg/kg PTX administered every 5 days (Figure 2A ). Although neither aIL-10R nor aCSF-1 mAb alone altered tumor growth kinetics relative to control mice over this time period, combinatorial PTX with either mAb significantly slowed tumor growth more effectively than PTX alone, with significant growth differences occurring following the second dose of PTX. No additional improvement was observed by combining aCSF-1 and aIL-10R mAbs plus PTX. Using a syngeneic orthotopic implantable PyMT explant model to evaluate survival, we observed greater than 2-fold increased survival with either aCSF-1 mAb/PTX or aIL-10R mAb/PTX (10 days) following initiation of treatment at approximately 1.0 cm in average tumor diameter, compared with mice treated with PTX alone (4.5 days) ( Figure 2B ). MMTV-PyMT mice treated with aIL-10R mAb also displayed an enhanced response to 50 mg/kg carboplatin (CBDCA), with tumors regressing approximately 50% over the course of treatment ( Figure 2C ). Using the C3(1)-TAg model of triple negative mammary carcinogenesis (Deeb et al., 2007; Maroulakou et al., 1994) we also found significant diminution of primary tumor growth when combining PTX with either aCSF-1 or aIL-10R mAbs ( Figure 2D ; Figures S2A-S2C) . Thus, the ability of IL-10 to limit chemotherapeutic efficacy was not limited by the type of chemotherapeutic or the subtype of mammary carcinoma being examined.
Regarding pulmonary metastasis, whereas aCSF-1 mAb/PTX diminished both the number and size of metastastic foci in MMTV-PyMT mice ( Figures 2E-2G ), inclusion of aIL-10R mAb in this regimen yielded no additional benefit. Neither aCSF-1 nor aIL-10R mAbs caused changes to proliferating cells (BrDU positivity) or cell death (cleaved caspase-3 positivity) in metastatic foci beyond that observed with PTX alone ( Figure S2D ). Our interpretation of these data was that whereas CSF-1R-activated macrophages produce epidermal growth factor (EGF) that in turn fosters neoplastic mammary epithelial cell invasion and metastasis (DeNardo et al., 2009; Lin et al., 2001 ), macrophage-derived IL-10 was not involved in programs regulating metastasis and instead represented a macrophage-dependent pathway within primary tumors regulating response to CTX.
Because a significant clinical issue theoretically limiting efficacy of CSF-1/CSF-1R-targeted therapy is perceived liver toxicity due to reduced density of liver Kupffer cells (Strachan et al., 2013; Wei et al., 2005) , we evaluated overall health of mice enrolled in these studies by several criteria. As expected, on the basis of a role for Kupffer cells in clearance of serum enzymes (Radi et al., 2011) , we observed increased serum alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase ( Figure S2E ) following aCSF-1 mAb therapy. Similar to what has been reported in nonhuman primates and rodents (Radi et al., 2011) , however, neutralizing CSF-1 alone or in combination yielded no adverse effects on animal health with respect to liver pathology, weight loss, or renal toxicity . No changes in animal health were noted with aIL-10R mAb alone or in combination. Thus, targeting of either IL-10R or CSF-1 improved efficacy of PTX without evidence of acute toxicity.
Improved Response to PTX Is CD8 + T Cell Dependent
To reveal mechanisms whereby macrophage IL-10 regulated response to CTX, we examined the presence of T cell populations in mammary tumors either 2 or 5 days following the final dose of PTX. Five days after PTX, aCSF-1 mAb or aCSF-1 mAb/PTX resulted in a small increase in the presence of CD4 + FoxP3 + T Reg cells, with no significant changes observed in CD4 + FoxP3 À T H cells or CD8 + T cells ( Figure S3A ). In contrast, in mammary tumors evaluated 2 days after PTX, aCSF-1 mAb and aCSF-1 mAb/PTX therapy resulted in a significant increase in the relative frequency of CD8 + T cells ( Figure 3A ). Because this change may have resulted from depletion of the major leukocyte population, we also evaluated the relative frequency of CD4 + T H cells and found no significant alteration in most groups (Figure 3B) , resulting in an increased CD8/CD4 T cell ratio within tumors from aCSF-1 mAb treated animals ( Figure 3C ). No changes were observed in CD4 + or CD8 + T cell infiltration following aIL-10R mAb or aIL-10R mAb/PTX therapy at either time point. Because increased CD8 + T cell infiltration was observed with aCSF-1 mAb even in the absence of CTX, and aCSF-1 mAb/PTX treatment increased mRNA expression of Gzmb in whole tissue ( Figure 1B ), we evaluated whether any of the combinatorial therapies increased the density of granzyme B (GZMB)-expressing cells, indicative of perhaps a ''better'' cytotoxic T lymphocyte response. Indeed, both aCSF-1 mAb/ PTX and aIL-10R mAb/PTX therapy increased tumor density of GZMB-positive cells 2 days after PTX by approximately 1.5-fold ( Figure 3D ). Increased presence of GZMB-positive cells was significant as CD8-depletion prior to PTX ablated improved outcomes for tumor-bearing mice treated with aIL-10R mAb/ PTX therapy ( Figure 3E ), similar to our previous finding using a CSF-1R antagonist (DeNardo et al., 2011) . Because macrophages isolated from MMTV-PyMT mammary tumors have been reported to exert immunosuppressive activity ex vivo (DeNardo et al., 2011; Doedens et al., 2010) , we next evaluated the role of IL-10 in mediating this activity. Notably, the ability of tumor-infiltrating macrophages to suppress splenic CD8 + T cell proliferation in vitro was largely isolated to the MHCII LO population (Figures 4E and 4F) , correlating with the presence of MHCII LO macrophages in areas of tumor hypoxia in situ (Figure 4G ) and higher expression of Arg1 ( Figure S1L ), similar to models of lung carcinogenesis (Laoui et al., 2014; Movahedi et al., 2010) . That said, neither aIL-10 neutralizing nor aIL-10R blocking mAb altered the immunosuppressive capacity of the MHCII HI or MHCII LO macrophage subset ex vivo ( Figure 4H ), and concordantly, addition of IL-10 did not suppress proliferation or expression of GZMB, interferon (IFN)-g, or tumor necrosis factor-a by CD8 + splenocytes during in vitro stimulation ( Figures S3B-S3E ). On the basis of these data, and the fact that IL-10 can promote IL-2-induced proliferation of human (Groux et al., 1998) and mouse CD8 + T cells (Chen and Zlotnik, 1991) when used at high concentrations (100 U/ml), we concluded that macrophage-derived IL-10 was likely regulating CD8 + T cell functionality indirectly. This conclusion was bolstered by the fact that gene expression programs in macrophages isolated from tumor-bearing mice treated with aIL-10R mAb were only modestly altered ( Figure S4 ), with the exception of reduced expression of Socs3, a downstream target gene of IL-10R signaling ( Figure 4I ).
IL-10 Does
Dendritic Cells Express High Levels of IL-10R
To address this hypothesis and identify cells infiltrating mammary tumors that potentially were being regulated by macrophage-derived IL-10, we evaluated expression patterns of IL-10R by flow cytometry. Although IL-10R expression has been observed on colonic epithelium (Denning et al., 2000) , the IL-10-binding subunit of IL-10R (IL-10Ra/IL-10R1) was restricted to CD45 + leukocytes in mammary tumors, with the exception of low expression by platelet-derived growth factor receptor a (PDGFRa) + fibroblasts ( Figure 5A ). To identify select lineages contributing to CD45 + expression, we isolated leukocyte subsets from mammary tumors as compared with equivalent populations from spleens (where possible) of non-tumor-bearing mice (Figure 5B increased by either aCSF-1 mAb/PTX or aIL-10R mAb/PTX treatment, although the effects of aCSF-1 mAb/PTX were more significant ( Figure 5C ). Immunofluorescent staining of carcinomas revealed that CD103 + cells (reflecting populations of DCs and CD8 + T cells) were dispersed throughout tumor stroma in proximity to F4/80 + macrophages, with limited invasion of the tumor parenchyma ( Figure 5D ). Although the density of CD103 + cells was increased by aCSF-1 mAb/PTX treatment, their localization appeared unchanged ( Figure 5D ). Because tumor macrophages and tumor DCs both express CD11c, albeit with higher surface expression by DCs See also Figure S3 .
Cancer Cell IL-10 Limits Chemotherapeutic Efficacy (Figure S1K ), we fluorescence-activated cell-sorted tumor macrophages, DCs, monocytes, and neutrophils to affirm the correct populations had been isolated (Figure S5 Figure S4 .
IL-10 Represses IL-12 Expression by DCs
Along with the increase in DC infiltration observed following either aIL-10R mAb/ PTX or aCSF-1 mAb/PTX therapy (Figure 5C ), we noted an almost 4-fold increase in Il12a expression in tumors from aCSF-1 mAb/PTX-treated mice ( Figure 1B ). Because CD8 + T cells in MMTV-PyMT mammary tumors expressed both subunits of the IL-12 receptor ( Figures S6A and S6B) , and IL-12 is known to enhance CD8 + T cell proliferation and effector function (Trinchieri, 2003) , we investigated a possible role for IL-10 in regulating IL-12 production by DCs and thereby influencing CD8 + T cell responses during CTX. To evaluate this, we first examined mRNA expression of the IL-12 subunits in sorted leukocyte populations. In mammary tumors from untreated mice, expression of Il12a mRNA was observed in most populations; however, mRNA expression of the p40 subunit of IL-12 (Il12b) was limited to DCs and macrophages ( Figure 6A ). Thus, although multiple leukocytes expressed Il12a mRNA, only DCs and macrophages appeared primed to produce IL-12. Indeed, IL-12p40 protein was only detectable by intracellular flow cytometry in a small population of tumor-associated CD103 + DCs (Figure 6B ), the cell type expressing the highest levels of Il12b mRNA.
IL-10 regulates IL-12 production by macrophages and DCs in vitro, depending on the type and kinetics of stimulation (D' Andrea et al., 1995; Koch et al., 1996) . We thus affirmed that preincubation with IL-10 prevented IFN-g/lipopolysaccharide (LPS)-and aCD40/LPS-induced production of IL-12p70 by FLT3-ligand matured bone marrow-derived DCs (BMDCs) (Figure 6C ). This regulation occurred at the level of mRNA expression, as IL-10 prevented upregulation of Il12a mRNA following aCD40/LPS stimulation ( Figure 6D ) and upregulation of Il12b mRNA ( Figure 6E ) and the corresponding IL-12p40 protein ( Figure S6C ) following stimulation by any combination of IFN-g, LPS, or aCD40. Although IL-10 can induce downregulation of some Toll-like receptor (TLR) signaling components (Knö dler et al., 2009) , IL-10's capacity to suppress IL-12 expression was not dependent on suppressed DC activation, as CD86 expression was only mildly reduced by IL-10 during stimulation with IFN-g/aCD40 or aCD40/LPS stimulation ( Figure S6D ). Because these data indicated that IL-10 regulated IL-12 expression at the mRNA level in vitro, we isolated macrophages and DCs from mammary tumors 2 days following the second dose of PTX (day 7) to determine whether IL-10 was functionally regulating IL-12 expression in myeloid cells in vivo. Consistent with our previous findings (Figure S4 ), aIL-10R mAb/PTX therapy did not alter expression of either gene in isolated macrophages (Figure 6F Figure 6F ). The upregulation of Il12b and detection of IL-12p40 at the protein level in CD103 + CD11b
À DCs indicates that these may be the critical source of IL-12 within mammary tumors; however, as IL-12p40 is produced in excess of IL-12p35, this is not definitive. To evaluate whether IL-12 was functionally significant with regard to the enhanced CD8-dependent responses observed in either aIL-10R mAb/PTX or aCSF-1 mAb/PTX-treated experimental groups, late-stage MMTV-PyMT mice were treated with a neutralizing antibody against either IL-12p40 (recognizing IL-12 and IL-23) or IL-12p70 (recognizing only IL-12) prior to administration of PTX. Although neither aIL-12p40 mAb nor aIL-12p70 mAb altered the response of tumors to PTX alone ( Figure 6G ), both neutralizing mAbs blocked the improved response to PTX observed following aIL-10R mAb therapy (Figure 6G) . Furthermore, consistent with our finding that macrophages were the primary source of IL-10 in mammary tumors (Figure 1 ), both IL-12 neutralizing antibodies also reversed the improved response to PTX observed following treatment with aCSF-1 mAb ( Figure 6G ).
IL12A Expression Correlates with Increased Pathologic Complete Response in Breast Cancer Patients
On the basis of these data indicating a significant role for IL-12 in mediating CD8 + T cells' responses to PTX in mammary carcinomas, we next evaluated whether IL12A or IL12B mRNA levels correlated with presence of DCs ( Figure 7A ) in human breast cancers using the TCGA data set (The Cancer Genome Atlas Network, 2012). Interestingly, only IL12A correlated with expression of transcription factors associated with DCs (CIITA) or the human equivalent of the CD103 + DC subset (BATF3, IRF8).
Expression of IL12A, but not IL12B, was also associated with evidence of a cytotoxic T cell response in these samples, as seen by a correlation with GZMB, CD8A, and IFNG expression ( Figure 7B ). On the basis of these associations, we next evaluated two published data sets annotated for pathologic complete response (pCR) following treatment with CTX (Hess et al., 2006; Tabchy et al., 2010) . Here, high expression of IL12A, along with the DC transcription factors and cytotoxic effector molecules, all were associated with an improved rate of pCR, with an $2-fold increase in the response rate observed for many of the genes ( Figure 7C ). Taken together, these results indicate an important cytokine axis in breast cancers wherein macrophage-derived IL-10 suppresses IL-12 production by DCs during CTX, thereby limiting cytotoxic CD8 + T cell responses in carcinomas (Figure 8 ).
Blockade of either the IL-10/IL-10R pathway or the CSF-1/CSF-1R pathway thus improves response to CTX and increases survival of tumor-bearing mice.
DISCUSSION
Herein we describe an interaction between macrophages and DCs in mammary tumor microenvironments, wherein macrophage-derived IL-10 indirectly blunts CD8 + T cell responses by inhibiting DC production of IL-12 following CTX. Tumorassociated macrophages have long been described to possess an immunosuppressive phenotype (Mantovani et al., 2002) , but the in vivo relevance of this phenotype has largely been inferred. Direct suppression by immature myeloid cells is usually linked to metabolism of L-arginine or production of free radicals (Gabrilovich and Nagaraj, 2009) . Supporting a role for these pathways in macrophage-mediated suppression, hypoxia promotes macrophage suppressive capacity and induces expression of arginase-1 (Doedens et al., 2010) , macrophages can suppress T cell proliferation through L-arginine depletion (Rodriguez et al., 2003) , and, as reported herein, MHCII LO macrophages exhibit tropism for hypoxic regions and exhibit enhanced suppressive capacity. However, the degree to which nutrient depletion in a closed in vitro system reflects the tumor microenvironment is unclear, and other studies have found that MHCII LO macrophages from implanted lung carcinoma models (Movahedi et al., 2010) and macrophages from human ovarian carcinoma ascites (Kryczek et al., 2006) suppress T cell proliferation independent of arginase and nitric oxide synthase activity. Human macrophages have instead been found to directly suppress T cell responses through programmed death-ligand 1 in hepatocellular carcinoma (Kuang et al., 2009 ) and B7-H4 in ovarian carcinoma (Kryczek et al., 2006) , and possibly indirectly through T Reg cell recruitment through CCL22 (Curiel et al., 2004) . Along with these studies, data presented herein describe a functional role for macrophages in mediating immune suppression within tumors, and ascribe this role to suppression of DC function. The drivers of Il10 expression by tumor macrophages are unclear. In general, Il10 expression by macrophages is thought to reflect activation by TLR ligands and type I IFN (Saraiva and O'Garra, 2010) . We noted modestly elevated expression of Il10 from MHCII LO macrophages, but although higher IL-10 secretion has also been observed in MHCII LO macrophages from implanted lung carcinomas (Laoui et al., 2014) , there is no evidence that hypoxia promotes Il10 expression. MHCII LO macrophages also expressed higher surface levels of IL-4Ra, but we previously reported that absence of CD4 + T cells did not influence IL-10 production by macrophages despite the ability of both IL-4 and IL-13 to promote IL-10 production in vitro (DeNardo et al., 2009) . Notably, mammary gland macrophages constitutively expressed Il10 at levels equivalent to that found in tumor macrophages, indicating that the homeostatic environment of the mammary gland is sufficient to promote Il10 expression, without a requirement for properties of the tumor microenvironment such as inflammation or hypoxia. 
(legend continued on next page)
Cancer Cell
IL-10 Limits Chemotherapeutic Efficacy
IL-10 has the potential to be expressed by most leukocyte populations (Saraiva and O'Garra, 2010) , as well as by normal and malignant epithelial cells (O'Garra et al., 2008) . Despite this extensive expression capacity, IL-10 production specifically by T Reg cells is critical for maintaining tolerance in the colon (Saraiva and O'Garra, 2010) , limiting T H 17 inflammation in tumors (Stewart et al., 2013) , and suppressing polyp formation (Dennis et al., 2013) . In contrast to the colon, we found that in mammary carcinomas, macrophages expressed the highest level of Il10 mRNA, with 10-fold lower expression observed in other leukocytes, and no expression observed by tumor epithelia. As the dominant immune population in murine mammary tumors, macrophages are thus the critical source of IL-10.
In human breast cancer, we similarly found no association between FOXP3 and IL10 expression but rather observed a correlation between IL10 expression and genes associated with either the presence (CSF1R, CD14, CD68) or polarization (CD163, MSR1) of macrophages. With no evidence of toxicity and the potential to simultaneously block multiple pro-tumorigenic macrophage pathways, targeting of the CSF-1/CSF-1R pathway continues to be an attractive therapeutic approach. That said, the increased diversity of leukocytic infiltrates in human breast cancer (Ruffell et al., 2012b) , and our observation that breast tumor epithelial cells expressed IL-10, argues that neutralizing the effects of IL-10 in human breast cancer may require more selective targeting to maximize a cytotoxic T cell response during CTX. This could take the form of a human aIL-10R blocking antibody, or kinase inhibitors against downstream IL-10R signaling components such as Janus kinase 1 or Signal transducer and activator of transcription 3. It might also be possible to enhance chemotherapeutic efficacy by directly activating myeloid cells to produce increased levels of IL-12, either alone or in combination with IL-10R antagonists. Although toxicity resulting from systemic myeloid activation is a concern, it is promising to note that a relatively safe CD40 agonist is in clinical trials (Beatty et al., 2013) .
IL-10 is often referred to as a pleiotropic cytokine, and its dual role in cancer likely reflects this. Both IL-10 deficiency and IL-10 overexpression can promote antitumor immune responses in mice (O'Garra et al., 2008) . Although IL-10-deficient mice are resistant to ultraviolet-induced skin carcinogenesis (Loser et al., 2007) , they are also sensitive to skin and colon carcinogenesis (Mumm et al., 2011; Sturlan et al., 2001) . Some of this disparity most assuredly reflects the significance of local tumor microenvironments in sculpting immune responses but also likely reflects local variations in bioavailable IL-10 (O'Garra et al., 2008) . IL-10 is a potent suppressor of DC activation, with even 1.0 U/ml largely ablating IL-12 secretion, as well as suppressing DC differentiation in vitro (Allavena et al., 1998) . On the other hand, high concentrations of IL-10 can promote IL-2-dependent proliferation of CD8 + T cells (Chen and Zlotnik, 1991; Groux et al., 1998) , and IL-10 is involved in CD8 + T cell memory formation in some, but not all, infection models (O'Garra et al., 2008) . This has led to divergent approaches for targeting IL-10 as an anticancer therapeutic: blocking IL-10R to enhance myeloid cell function (Vicari et al., 2002) versus injecting exogenous IL-10 to directly promote an antitumor T cell response through activation of intratumoral CD8 + T cells (Emmerich et al., 2012; Mumm et al., 2011) . CD8 + T cells in mammary tumors of MMTV-PyMT did not express IL-10R, indicating that exogenous IL-10 would likely prove ineffective in this context, but ongoing clinical studies will determine the validity of this approach in patients. Blocking IL-10R has not been used extensively as an approach for anticancer therapy but has been reported to induce tumor regression in combination with CpG oligonucleotides in various subcutaneous tumor models, ostensibly through macrophage/DC activation and increased expression of IL-12 (Guiducci et al., 2005; Vicari et al., 2002) . In sharp contrast to these studies, response to CTX in subcutaneous tumor models has been found to occur independently of IL-12 and Batf3-dependent DCs and is instead mediated by an immune cell/ cytokine pathway involving IFN-b, IL-17, and IFN-g, with production by CD11b + CD103 + DCs, gd T cells, and CD8 + T cells, respectively (Kroemer et al., 2013; Ma et al., 2013) . The importance of this pathway for response to CTX has been called into question using transgenic models of mammary carcinoma, as these respond to CTX independently of adaptive immune cells, with the suggestion that this is due to the use of implantable versus spontaneous tumors (Ciampricotti et al., 2012) . We instead suggest that these differences are due at least partially to anatomical location. Thus, preventing macrophage infiltration via aCSF-1 mAbs (or CSF-1R antagonists) or limiting macrophage functionality via aIL-10R mAbs, enables CTX and resultant cell death to benefit from productive CD8 + T cell responses elicited in tumors. However, unlike subcutaneous models, our data indicate a critical role for IL-12 and possibly CD103 + DCs, again highlighting the role of anatomical location in determining response to therapy. This concept has been elegantly demonstrated in a recent study in which subcutaneously implanted tumors were found to be more sensitive to immunotherapy than the same cell lines implanted orthotopically (Devaud et al., 2014) . DCs in solid tumors are generally viewed as critical primers of de novo T cell responses (Chen and Mellman, 2013) , and therapeutic targeting of DCs has focused on this aspect. Our data do not definitively demonstrate a role for DCs within mammary tumors, and systemic suppression of DC function through IL-10 has been observed (Yang and Lattime, 2003) . At the same time, however, removal of tumor-draining lymph nodes from mice bearing subcutaneous tumors did not alter response to CTX (Ma et al., 2013) , tertiary lymphoid structures have been implicated in T cell activity in melanoma , and the presence of follicular helper T cells correlates positively with patient outcome and response to CTX in breast cancer (Bindea et al., 2013; Gu-Trantien et al., 2013) . These studies align well with our finding that gene expression indicative of a CD8 + (G) Relative tumor volume after 3 rounds of PTX in MMTV-PyMT transgenic mice following combination therapy with aCSF-1 mAb or aIL-10R mAb. IL-12 neutralizing mAb (aIL-12p40 or aIL-12p70) was administered concurrently every 5 days. Data are displayed as mean ± SEM, with n R 5 mice per group. Significance was determined by an unpaired t test, with *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S6 .
T cell response (GZMB, CD8A, IFNG) or the presence of DCs (IL12A, CIITA, IRF8) coincides with improved response to neoadjuvant CTX, and together hint at the importance of favorable DC activity within the tumor microenvironment promoting an antitumor immune response to CTX. Animal Care and Use FVB/n strain background mice harboring the PyMT transgene under the control of the MMTV promoter (Guy et al., 1992) , and the simian virus 40 large tumor antigen (SV40 TAg) under control of the rat prostatic steroid binding protein gene [C3 (1)] (Maroulakou et al., 1994) , have been previously described. Implantation of orthotopic mammary tumors was performed as described (DeNardo et al., 2011 ) using single-cell suspensions from mammary tumors of d80-d85 MMTV-PyMT transgenic mice combined 1:1 with Matrigel (BD Biosciences). Treatment schedules were initiated as indicated in the respective figures. mAbs (aCSF-1/5A1, aIL-10R/1B1.3A, aCD8/2.43, IgG 1 / HRPN, aIL-12p75/R2-9A5, and aIL-12p40/C17.8) were obtained from BioXCell and were administered by intraperitoneal injection at 1.0 mg/mouse, with follow-up doses of 0.5 mg every 5 days. Clinical grade PTX (Hospira) or carboplatin (Novaplus) was administered intravenously every 5 days at 10 mg/kg or 50 mg/kg, respectively. Before terminal cardiac perfusion with PBS containing 10 U/ml of heparin (Sigma-Aldrich), mice were intraperitoneally injected with 50 mg/kg BrdU (Roche) for 90 min. Resected tissues were either flash frozen in liquid nitrogen, directly embedded in optimal cutting temperature (Sakura Finetek) medium after resection, or incubated overnight in neutral buffered formalin prior to ethanol dehydration and paraffin embedding. Mice were maintained either within the UCSF Laboratory for Animal Care barrier facility or the Oregon Health & Science University Department of Comparative Medicine barrier facility. All experiments involving animals were approved by the respective institutional animal care and use committees.
Statistical Analysis
Statistical analyses were performed using Prism (GraphPad). Statistical significance was determined via an unpaired t test, an unpaired t test with Welch's correction, 2-way analysis of variance (ANOVA), or Mann-Whitney test as indicated. Heatmaps were generated GENE-E software (http://www. broadinstitute.org/cancer/software/GENE-E/). All heatmaps are displayed on a logarithmic scale with values normalized per row, with hierarchical clustering performed with a 1 minus Pearson correlation. Linear regression analysis in breast cancer was performed in Prism using the TCGA data set (The Cancer Genome Atlas Network, 2012) . Gene expression data from fine-needle aspirate obtained prior to neoadjuvant CTX in breast cancer patients were obtained from 2 published data sets (GSE20194 and GSE20271) annotated for pCR (Hess et al., 2006; Tabchy et al., 2010) . Peprotech), LPS-EB Ultrapure (100 ng/ml; InvivoGen), or αCD40 (10 µg/ml; FGK4.5; BioXCell). For intracellular flow cytometry, Brefeldin A (3.0 µg/ml; eBioscience) was added 4 hours prior to harvesting the cells.
T cell activation
Splenic CD8 + T cells were purified by magnetic negative selection (Stem Cell Technologies) to over 95% purity and labeled with Cell Trace Violet (Invitrogen). CD8 + T cells (10 5 ) were then placed a 96-well plate coated with 5.0 µg/ml αCD3 (145.2C11) and αCD28 (PV-1) antibodies in RPMI1640 containing 2.0 mM Lglutamine and 25 mM HEPES, supplemented with 10 mM Sodium Pyruvate, 100 U/ml penicillin/streptocmycin, 55 µM B-ME, and 10% fetal calf serum (Life Technologies) for 48 hrs at 37°C.
Brefeldin A (3.0 µg/ml; eBioscience) was added 4 hours prior to harvesting the cells for intracellular staining with GZMB PE, IFN-γ APC, and TNF-α PE-Cy7. Data acquisition was performed on a BD Fortessa flow cytometer with analysis using FlowJo software.
T cell suppression assay
Splenic CD8 + T cells were purified by magnetic negative selection (Stem Cell Technologies) to over 95% purity and labeled with Cell Trace Violet (Invitrogen). CD8 + T cells (10 5 ) were then placed in a 96-well plate coated with 5 µg/ml αCD3 (145.2C11) and αCD28 (PV-1) antibodies. After a brief spin, FACSsorted macrophages from MMTV-PyMT late stage tumors were added into wells at various ratios with or without 10 µg/ml of blocking/neutralizing antibodies. Cells were cultured together in RPMI1640 containing 2.0 mM L-glutamine and 25 mM HEPES, supplemented with 10 mM Sodium Pyruvate, 100 U/ml penicillin/streptocmycin, 55 µM B-ME, and 10% fetal calf serum (Life Technologies) for 60 hrs at 37°C.
Cells were then stained with CD8-PE, CD11b-APC and 7AAD prior to analysis on an LSRII or Fortessa flow cytometer. The replication index was determined using FlowJo software.
Quantitation of paclitaxel
Mice bearing orthotopic mammary tumors were intravenously injected with 10 mg/kg paclitaxel and, following a cardiac puncture blood draw, were perfused to clear peripheral blood. Tumor and liver tissues were snap-frozen in liquid nitrogen. Liquid chromatography-mass spectrometry was performed on homogenized samples by Integrated Analytical Solutions (Berkeley, CA) using the injected compound as a reference sample.
